Back to Search Start Over

Screening for liver X receptor modulators: Where are we and for what use?

Authors :
Buñay, Julio
Fouache, Allan
Trousson, Amalia
de Joussineau, Cyrille
Bouchareb, Erwan
Zhu, Zhekun
Kocer, Ayhan
Morel, Laurent
Baron, Silvere
Lobaccaro, Jean‐Marc A.
Lobaccaro, Jean-Marc A
Source :
British Journal of Pharmacology; Aug2021, Vol. 178 Issue 16, p3277-3293, 17p, 3 Diagrams, 1 Chart, 1 Graph
Publication Year :
2021

Abstract

Liver X receptors (LXRs) are members of the nuclear receptor superfamily that are canonically activated by oxidized derivatives of cholesterol. Since the mid-90s, numerous groups have identified LXRs as endocrine receptors that are involved in the regulation of various physiological functions. As a result, when their expression is genetically modified in mice, phenotypic analyses reveal endocrine disorders ranging from infertility to diabetes and obesity, nervous system pathologies such Alzheimer's or Parkinson's disease, immunological disturbances, inflammatory response, and enhancement of tumour development. Based on such findings, it appears that LXRs could constitute good pharmacological targets to prevent and/or to treat these diseases. This review discusses the various aspects of LXR drug discovery, from the tools available for the screening of potential LXR modulators to the current situational analysis of the drugs in development. LINKED ARTICLES: This article is part of a themed issue on Oxysterols, Lifelong Health and Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.16/issuetoc. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00071188
Volume :
178
Issue :
16
Database :
Complementary Index
Journal :
British Journal of Pharmacology
Publication Type :
Academic Journal
Accession number :
151661053
Full Text :
https://doi.org/10.1111/bph.15286